All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Serdexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: KP879
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2021
Details:
KP879 is being developed as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD), a condition for which there are no FDA-approved medications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cannabinoids
Therapeutic Area: Psychiatry/Psychology Product Name: RLS 103
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2021
Details:
Receptor Life Sciences has completed a pre-investigational new drug meeting with the U.S. FDA. The meeting resulted in clear guidance on the regulatory requirements for the development and approval of RLS103 under section 505(b)(2).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Drinabant
Therapeutic Area: Psychiatry/Psychology Product Name: OPNT004
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Funding January 08, 2021
Details:
IRISYS, has been awarded by the National Center for Advancing Translational Sciences (NCATS), one of 27 institutes of the NIH, to develop a new injectable formulation of Drinabant, a selective, high affinity cannabinoid receptor (CB-1) antagonist.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: CUREfilm Blue
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Serdexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: KP879
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
KemPharm is developing KP879 as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD). If the KP879 IND filing is accepted by the FDA, KemPharm intends to initiate efficacy studies of KP879 in 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MEB-1170
Therapeutic Area: Psychiatry/Psychology Product Name: MEB-1170
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $7.1 million Upfront Cash: Undisclosed
Deal Type: Funding October 29, 2020
Details:
The funds will be used to progress the company's lead candidate MEB–1170, an analgesic drug candidate for the prevention and treatment of Opioid Use Disorder, through IND filing and Phase 1 clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: BXCL501
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
BXCL501 is an investigational, proprietary, orally dissolving, sublingual thin film formulation of dexmedetomidine, for the treatment of acute agitation. The Company plans to initiate a Phase 2 trial within the next several months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
The potential advantage of this alternative dosage form of Quetiapine Fumarate is that it may be preferred for adult patients who experience swallowing difficulties or for adults and adolescents who have trouble swallowing tablets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PT00114
Therapeutic Area: Psychiatry/Psychology Product Name: PT00114
Highest Development Status: IND Enabling Product Type: Peptide
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 08, 2020
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
